Tempest Therapeutics Inc. has announced its entry into a securities purchase agreement with a single institutional investor, as detailed in a recent prospectus filed with the Securities and Exchange Commission. The agreement allows Tempest to issue and sell 405,000 shares of common stock and prefunded warrants for 334,000 additional shares in a registered direct offering. The offering, priced at $6.25 per share of common stock and $6.249 per prefunded warrant, is aimed at raising funds to support strategic alternatives and general corporate purposes. The net proceeds, combined with existing cash reserves, are expected to fund the company's operations into the second quarter of 2026, although this estimate may change based on future financial needs. The company has engaged Cooley LLP to provide a legal opinion on the validity of the securities being issued.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。